Thursday, June 7, 2012
Hyperion Therapeutics Inc., of South San Francisco, said a 178-patient Phase II study of glycerol phenylbutyrate, a pre-prodrug of phenylacetic acid, in episodic hepatic encephalopathy (HE) met its primary endpoint.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.